Aurinia Pharmaceuticals (AUPH) Change in Account Payables (2024 - 2026)

Aurinia Pharmaceuticals has reported Change in Account Payables for 3 years, with the latest figure at -$652000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 33.06% year-over-year to -$652000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.6 million (down 6.37% YoY), and the FY2025 full-year result was -$1.9 million, down 317.91% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$652000.0, down from $1.1 million in the prior quarter.
• The five-year high for Change in Account Payables was $2.7 million in Q2 2024, with the low at -$3.7 million in Q4 2024.
• Historically, Change in Account Payables has averaged -$185111.1 across 3 years, with a median of -$652000.0 in 2026.
• The largest YoY upside for Change in Account Payables was 129.78% in 2025 against a maximum downside of 337.15% in 2025.
• Aurinia Pharmaceuticals' Change in Account Payables stood at -$3.7 million in 2024, then soared by 129.78% to $1.1 million in 2025, then tumbled by 159.33% to -$652000.0 in 2026.
• The last three Change in Account Payables figures came in at -$652000.0 (Q1 2026), $1.1 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.